Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -306.61% is 118% below its 4-year average of -140.56%, near the low end of its 4-year range (-306.61%–-71.91%).
As of the fiscal period ended Tuesday, June 30, 2026. 74.67% below its 12-month average of -175.54%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -306.61%.
RETURN ON EQUITY (ROE)
-306.61%
RETURN ON EQUITY (ROE) AVG TTM
-175.54%
RETURN ON EQUITY (ROE) AVG 3Y
-149.45%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-74.67%
CURRENT VS 3Y AVG
-105.16%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-629.84%
vs the sector median at left
Nuvectis Pharma, Inc.
Market Cap
$531.52M
Return on Equity (ROE)
-306.61%
TTM Avg
-175.54%
3Y Avg
-149.45%
5Y Avg
N/A
Market Cap
$531.98M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$533.04M
Return on Equity (ROE)
-13.64%
TTM Avg
-19.13%
3Y Avg
-73.22%
5Y Avg
-63.52%
Market Cap
$529.58M
Return on Equity (ROE)
-24.90%
TTM Avg
-76.97%
3Y Avg
-68.04%
5Y Avg
-50.09%
Market Cap
$538.01M
Return on Equity (ROE)
N/A
TTM Avg
6.49%
3Y Avg
6.51%
5Y Avg
-75.00%
Market Cap
$524.43M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$519.25M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
Market Cap
$516.76M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$548.51M
Return on Equity (ROE)
N/A
TTM Avg
91.17%
3Y Avg
180.92%
5Y Avg
76.31%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $531.52M | -306.61% | -175.54% | -149.45% | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 0.44% | -17.98% | 71.24% | -6.51% |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | -13.64% | -19.13% | -73.22% | -63.52% |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | -24.90% | -76.97% | -68.04% | -50.09% |
| ProKidney Corp. (PROK)vs › | $538.01M | N/A | 6.49% | 6.51% | -75.00% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | -17.44% | -97.25% | -87.77% | -77.06% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -19.35% | -58.07% | -51.86% | -46.32% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | -60.79% | -73.94% | -62.04% | -71.62% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | N/A | 91.17% | 180.92% | 76.31% |
| 908 Devices Inc. (MASS)vs › | $505.87M | -27.20% | -44.25% | -32.03% | -24.61% |
ROE
-306.6%
ROA
-124.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -306.61% |
| 2026-03-31 | -191.00% |
| 2025-12-31 | -143.61% |
| 2025-09-30 | -105.69% |
| 2025-06-30 | -130.79% |
| 2025-03-31 | -96.22% |
| 2024-12-31 | -195.61% |
| 2024-09-30 | -176.27% |
| 2024-06-30 | -168.44% |
| 2024-03-31 | -159.62% |
| 2023-12-31 | -182.44% |
| 2023-09-30 | -133.85% |
| 2023-06-30 | -109.83% |
| 2023-03-31 | -164.50% |
| 2022-12-31 | -134.22% |
| 2022-09-30 | -71.91% |
| 2022-06-30 | -116.88% |
| 2022-03-31 | -108.59% |
